# Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy

> **NCT02814864** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 12 (estimated)

## Conditions studied

- Pelvic Radiation Therapy
- Radiation-induced Hemorrhagic Cystitis

## Interventions

- **DRUG:** Mesenchymal Stromal Cell (MSC) injections

## Key facts

- **NCT ID:** NCT02814864
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-14
- **Primary completion:** 2022-04
- **Final completion:** 2022-04
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02814864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02814864, "Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02814864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*